AIMS: To investigate the safety, pharmacokinetics and pharmacodynamics of the new cathepsin K inhibitor, ONO-5334. METHODS: A double-blind, placebo-controlled, randomized study was carried out in 52 healthy post menopausal females. Single ascending doses of ONO-5334 (3-600 mg) were evaluated in six cohorts. The effect of food was studied at ONO-5334 100 mg. RESULTS: Across the doses tested, mean ONO-5334 C(max) occurred 0.5-1.0 h after dosing and the the t(1/2) ranged from 9.1 to 22 h. Linear increases in C(max) and AUC(0,∞) were observed in the 3-300 mg and 3-600 mg dose range, respectively. After food, the geometric mean ratio (95% CI) C(max) and AUC(0,∞) for ONO-5334 were 0.78 (0.31, 1.94) and 0.95 (0.67, 1.35)-fold greater than fasted, respectively. ONO-5334 significantly reduced serum bone resorption markers within 4 h vs. placebo. Statistical significance was achieved for ONO-5334 doses ≥30 mg for C-terminal telopeptide of type 1 collagen (CTX) and ≥300 mg for N-terminal telopeptide of type 1 collagen (NTX). Statistical significance was still evident at 24 h for ONO-5334 100 mg with serum CTX and 600 mg with serum NTX. The maximum suppression in serum CTX occurred at 4 h post dose with difference compared with placebo of -32%, -59%, -60% and -66% for 30, 100, 300 and 600 mg ONO-5334, respectively. Second morning urine void 24 h post dose showed statistically significant suppression of urinary CTX and NTX at 100 mg and above vs. placebo. ONO-5334 600 mg showed statistically significant suppression up to 72 h for serum CTX, urinary CTX and urinary NTX and 48 h for serum NTX vs. placebo. Adverse events were transient with no evidence of dose relationship. CONCLUSIONS:ONO-5334 displayed linear plasma pharmacokinetics over the (predicted therapeutic) dose range, 3-300 mg, with clear suppression of urinary bone resorption markers at doses ≥100 mg for serum markers at 24 h. ONO-5334 was well tolerated up to 600 mg day(-1) when administered to healthy post menopausal women.
RCT Entities:
AIMS: To investigate the safety, pharmacokinetics and pharmacodynamics of the new cathepsin K inhibitor, ONO-5334. METHODS: A double-blind, placebo-controlled, randomized study was carried out in 52 healthy post menopausal females. Single ascending doses of ONO-5334 (3-600 mg) were evaluated in six cohorts. The effect of food was studied at ONO-5334 100 mg. RESULTS: Across the doses tested, mean ONO-5334 C(max) occurred 0.5-1.0 h after dosing and the the t(1/2) ranged from 9.1 to 22 h. Linear increases in C(max) and AUC(0,∞) were observed in the 3-300 mg and 3-600 mg dose range, respectively. After food, the geometric mean ratio (95% CI) C(max) and AUC(0,∞) for ONO-5334 were 0.78 (0.31, 1.94) and 0.95 (0.67, 1.35)-fold greater than fasted, respectively. ONO-5334 significantly reduced serum bone resorption markers within 4 h vs. placebo. Statistical significance was achieved for ONO-5334 doses ≥30 mg for C-terminal telopeptide of type 1 collagen (CTX) and ≥300 mg for N-terminal telopeptide of type 1 collagen (NTX). Statistical significance was still evident at 24 h for ONO-5334 100 mg with serum CTX and 600 mg with serum NTX. The maximum suppression in serum CTX occurred at 4 h post dose with difference compared with placebo of -32%, -59%, -60% and -66% for 30, 100, 300 and 600 mg ONO-5334, respectively. Second morning urine void 24 h post dose showed statistically significant suppression of urinary CTX and NTX at 100 mg and above vs. placebo. ONO-5334 600 mg showed statistically significant suppression up to 72 h for serum CTX, urinary CTX and urinary NTX and 48 h for serum NTX vs. placebo. Adverse events were transient with no evidence of dose relationship. CONCLUSIONS:ONO-5334 displayed linear plasma pharmacokinetics over the (predicted therapeutic) dose range, 3-300 mg, with clear suppression of urinary bone resorption markers at doses ≥100 mg for serum markers at 24 h. ONO-5334 was well tolerated up to 600 mg day(-1) when administered to healthy post menopausal women.
Authors: P A C Cloos; C Fledelius; S Christgau; C Christiansen; M Engsig; P Delmas; J-J Body; P Garnero Journal: Calcif Tissue Int Date: 2002-10-21 Impact factor: 4.333
Authors: Morten A Karsdal; Thomas J Martin; Jens Bollerslev; Claus Christiansen; Kim Henriksen Journal: J Bone Miner Res Date: 2007-04 Impact factor: 6.741
Authors: J Y Reginster; Y Henrotin; C Christiansen; E Gamwell-Henriksen; J Collette; S Christgau Journal: Calcif Tissue Int Date: 2001-09 Impact factor: 4.333
Authors: Y Nishi; L Atley; D E Eyre; J G Edelson; A Superti-Furga; T Yasuda; R J Desnick; B D Gelb Journal: J Bone Miner Res Date: 1999-11 Impact factor: 6.741
Authors: M Gowen; F Lazner; R Dodds; R Kapadia; J Feild; M Tavaria; I Bertoncello; F Drake; S Zavarselk; I Tellis; P Hertzog; C Debouck; I Kola Journal: J Bone Miner Res Date: 1999-10 Impact factor: 6.741
Authors: S A Stoch; S Zajic; J Stone; D L Miller; K Van Dyck; M J Gutierrez; M De Decker; L Liu; Q Liu; B B Scott; D Panebianco; B Jin; L T Duong; K Gottesdiener; J A Wagner Journal: Clin Pharmacol Ther Date: 2009-05-06 Impact factor: 6.875
Authors: Bennett Ma; Bin Luo; Danielle H Euler; Tara E Cusick; Gregg Wesolowski; Helmut Glantschnig; Le T Duong; Yangsi Ou; Steven S Carroll; Laura S Lubbers Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-02-20 Impact factor: 3.000